BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 32866497)

  • 1. FAM122A maintains DNA stability possibly through the regulation of topoisomerase IIα expression.
    Wang YQ; Yang YS; Chen J; Liu MH; Chen GQ; Huang Y
    Exp Cell Res; 2020 Nov; 396(1):112242. PubMed ID: 32866497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAM122A supports the growth of hepatocellular carcinoma cells and its deletion enhances Doxorubicin-induced cytotoxicity.
    Zhou Y; Shi WY; He W; Yan ZW; Liu MH; Chen J; Yang YS; Wang YQ; Chen GQ; Huang Y
    Exp Cell Res; 2020 Feb; 387(1):111714. PubMed ID: 31711919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
    Kont YS; Dutta A; Mallisetty A; Mathew J; Minas T; Kraus C; Dhopeshwarkar P; Kallakury B; Mitra S; Üren A; Adhikari S
    DNA Repair (Amst); 2016 Jul; 43():38-47. PubMed ID: 27235629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
    Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
    J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9 Genome Editing of the Human Topoisomerase II
    Hernandez VA; Carvajal-Moreno J; Papa JL; Shkolnikov N; Li J; Ozer HG; Yalowich JC; Elton TS
    Mol Pharmacol; 2021 Mar; 99(3):226-241. PubMed ID: 33446509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
    Bhosle J; Kiakos K; Porter AC; Wu J; Makris A; Hartley JA; Hochhauser D
    Mol Cancer Ther; 2013 Dec; 12(12):2897-908. PubMed ID: 24092808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular processing pathways contribute to the activation of etoposide-induced DNA damage responses.
    Fan JR; Peng AL; Chen HC; Lo SC; Huang TH; Li TK
    DNA Repair (Amst); 2008 Mar; 7(3):452-63. PubMed ID: 18206427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of topoisomerase II stability and activity by ubiquitination and SUMOylation: clinical implications for cancer chemotherapy.
    Ma Y; North BJ; Shu J
    Mol Biol Rep; 2021 Sep; 48(9):6589-6601. PubMed ID: 34476738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of CRISPR/Cas9 with homology-directed repair to silence the human topoisomerase IIα intron-19 5' splice site: Generation of etoposide resistance in human leukemia K562 cells.
    Hernandez VA; Carvajal-Moreno J; Wang X; Pietrzak M; Yalowich JC; Elton TS
    PLoS One; 2022; 17(5):e0265794. PubMed ID: 35617303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.
    Menendez D; Anand JR; Murphy CC; Bell WJ; Fu J; Slepushkina N; Buehler E; Martin SE; Lal-Nag M; Nitiss JL; Resnick MA
    Oncotarget; 2022; 13():332-346. PubMed ID: 35178190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
    Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
    Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioflavonoids cause DNA double-strand breaks and chromosomal translocations through topoisomerase II-dependent and -independent mechanisms.
    Goodenow D; Emmanuel F; Berman C; Sahyouni M; Richardson C
    Mutat Res Genet Toxicol Environ Mutagen; 2020 Jan; 849():503144. PubMed ID: 32087851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rac1 protein signaling is required for DNA damage response stimulated by topoisomerase II poisons.
    Huelsenbeck SC; Schorr A; Roos WP; Huelsenbeck J; Henninger C; Kaina B; Fritz G
    J Biol Chem; 2012 Nov; 287(46):38590-9. PubMed ID: 23012366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosyl-DNA-phosphodiesterase I (TDP1) participates in the removal and repair of stabilized-Top2α cleavage complexes in human cells.
    Borda MA; Palmitelli M; Verón G; González-Cid M; de Campos Nebel M
    Mutat Res; 2015 Nov; 781():37-48. PubMed ID: 26421495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The polyphenolic ellagitannin vescalagin acts as a preferential catalytic inhibitor of the α isoform of human DNA topoisomerase II.
    Auzanneau C; Montaudon D; Jacquet R; Puyo S; Pouységu L; Deffieux D; Elkaoukabi-Chaibi A; De Giorgi F; Ichas F; Quideau S; Pourquier P
    Mol Pharmacol; 2012 Jul; 82(1):134-41. PubMed ID: 22528119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A DNA repair player, ring finger protein 43, relieves etoposide-induced topoisomerase II poisoning.
    Lerksuthirat T; Wikiniyadhanee R; Stitchantrakul W; Chitphuk S; Stansook N; Pipatpanyanugoon N; Jirawatnotai S; Dejsuphong D
    Genes Cells; 2020 Nov; 25(11):718-729. PubMed ID: 32939879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NEK5 interacts with topoisomerase IIβ and is involved in the DNA damage response induced by etoposide.
    Melo-Hanchuk TD; Slepicka PF; Pelegrini AL; Menck CFM; Kobarg J
    J Cell Biochem; 2019 Oct; 120(10):16853-16866. PubMed ID: 31090963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of CRISPR/Cas9 with Homology-Directed Repair to Gene-Edit Topoisomerase II
    Carvajal-Moreno J; Wang X; Hernandez VA; Mondal M; Zhao X; Yalowich JC; Elton TS
    J Pharmacol Exp Ther; 2024 Apr; 389(2):186-196. PubMed ID: 38508753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase IIα, rather than IIβ, is a promising target in development of anti-cancer drugs.
    Chen W; Qiu J; Shen YM
    Drug Discov Ther; 2012 Oct; 6(5):230-7. PubMed ID: 23229142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.